These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16137751)

  • 21. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA2 mutation carriers, reproductive factors and breast cancer risk.
    Tryggvadottir L; Olafsdottir EJ; Gudlaugsdottir S; Thorlacius S; Jonasson JG; Tulinius H; Eyfjord JE
    Breast Cancer Res; 2003; 5(5):R121-8. PubMed ID: 12927042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
    Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
    Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
    Narod SA; Risch H; Moslehi R; Dørum A; Neuhausen S; Olsson H; Provencher D; Radice P; Evans G; Bishop S; Brunet JS; Ponder BA
    N Engl J Med; 1998 Aug; 339(7):424-8. PubMed ID: 9700175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study.
    Beiner ME; Finch A; Rosen B; Lubinski J; Moller P; Ghadirian P; Lynch HT; Friedman E; Sun P; Narod SA;
    Gynecol Oncol; 2007 Jan; 104(1):7-10. PubMed ID: 16962648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
    Rafnar T; Benediktsdottir KR; Eldon BJ; Gestsson T; Saemundsson H; Olafsson K; Salvarsdottir A; Steingrimsson E; Thorlacius S
    Eur J Cancer; 2004 Dec; 40(18):2788-93. PubMed ID: 15571962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
    Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.
    Liede A; Karlan BY; Narod SA
    J Clin Oncol; 2004 Feb; 22(4):735-42. PubMed ID: 14966099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of HRT and the subsequent risk of cancer.
    Beral V; Banks E; Reeves G; Appleby P
    J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing.
    Dorval M; Vallée MH; Plante M; Chiquette J; Gaudet M; Simard J
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):157-60. PubMed ID: 17220345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.
    Goldfrank D; Chuai S; Bernstein JL; Ramon Y Cajal T; Lee JB; Alonso MC; Diez O; Baiget M; Kauff ND; Offit K; Robson M
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2311-3. PubMed ID: 17119064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.